Italy-based Kedrion SpA, a company involved in the development of new anti-COVID therapies together with its research partner Columbia University Irving Medical Center in New York, has named Val Romberg as its new CEO, it was reported on Tuesday.

Most recently, Romberg was executive vice president of Operations for CSL Behring. He has over 40 years of experience serving various companies including West Pharmaceutical Services, Aventis Behring, ZLB Behring and CSL Behring.

Paolo Marcucci, the Kedrion group chairman, said, Romberg 'is a great fit with a top manager who shares our strategic vision for the future. I am glad to welcome Val Romberg to Team Kedrion, and I am pleased that he recognises our work with Columbia University, which we regard as a priority project.'